eGFR blood test
Estimated glomerular filtration rate. Also called: Estimated GFR, eGFRcr, GFR, estimated
eGFR estimates how much blood the kidneys filter each minute, calculated from serum creatinine, age and sex. Labcorp and Quest use the 2021 CKD-EPI equation, which dropped the race adjustment of earlier formulas.
At a glance
| What it measures | An estimate of kidney filtering (glomerular filtration rate), calculated from serum creatinine, age and sex. |
|---|---|
| Sample | Blood (serum), the same sample as creatinine. No fasting is required, but a cooked-meat meal or hard exercise beforehand can lower it. |
| Typical adult range | Labcorp: above 59 mL/min/1.73 m². Quest: 60 or above. Normal young adults are about 120-130, and it falls with age. |
| Common reasons it reads low | Chronic kidney disease, dehydration, ageing, a cooked-meat meal, hard exercise, high muscle mass, trimethoprim and other drugs that block creatinine secretion. |
| Peptides that move it | Slower decline vs placebo with Semaglutide (FLOW); less decline than insulin glargine with Dulaglutide. No clear effect with Tirzepatide, Liraglutide or Lixisenatide. |
| Lab code | LOINC 98979-8, CKD-EPI 2021 creatinine (Labcorp 100768, Quest 375) |
What is eGFR?
The glomerular filtration rate (GFR) is the volume of fluid the kidneys filter out of the blood each minute. Measuring it directly means infusing a marker such as inulin and timing its clearance, so labs estimate it from serum creatinine instead.
Labcorp and Quest both calculate eGFR with the CKD-EPI 2021 creatinine equation, which uses creatinine, age and sex but not race. Guidelines recommend creatinine with an eGFR as the first step in assessing kidney function.
How it is made and regulated
Where it is made
Filtration happens in the glomeruli and depends on the pressure difference set by the arterioles feeding and draining them. It rises by 40-65% in normal pregnancy, and early in diabetes many people have abnormally high filtration (hyperfiltration).
What controls it
Prostaglandins help keep kidney blood flow and filtration up when circulating volume is low, an important compensating mechanism when kidney perfusion falls. Cyclooxygenase inhibitors (NSAIDs) block prostaglandin production.
Sources: [7]
How it travels in the blood
The CKD-EPI 2021 creatinine equation was developed in 8,254 people (31.5% Black) and checked against measured GFR in 4,050 more; 85% or more of its estimates fell within 30% of measured GFR. A version that adds cystatin C is more accurate.
Sources: [4]
How long it lasts
eGFR assumes creatinine is stable. After a sudden change in kidney function, creatinine takes from about 1.1 to 13.4 days to settle at its new level, so an eGFR taken while kidney function is changing quickly lags behind the true value.
Sources: [8]
What it does
GFR falls with age, usually from 30-40 years and perhaps faster after 50-60; in carefully screened kidney donors it fell by 6.3 mL/min/1.73 m² per decade. eGFR is used to stage chronic kidney disease into categories G1 to G5.
Reference ranges
Labs report a single lower limit for adults rather than an age-specific range. Labcorp also prints the KDIGO GFR categories used to stage chronic kidney disease. Normal young adults run about 120-130, and eGFR falls with age.
Labcorp (test 100768)
| Group | Range (mL/min/1.73 m²) |
|---|---|
| Adults | Above 59 |
Labcorp has used the 2021 CKD-EPI creatinine equation without a race coefficient since Feb. 28, 2022. Result LOINC 98979-8.
Labcorp (test 100768)
| Group | Range (mL/min/1.73 m²) |
|---|---|
| G1: normal or high | 90 or above |
| G2: mildly decreased (relative to young adult level) | 60-89 |
| G3a: mildly to moderately decreased | 45-59 |
| G3b: moderately to severely decreased | 30-44 |
| G4: severely decreased | 15-29 |
| G5: kidney failure | Below 15 |
Categories, not a normal range. Without evidence of kidney damage, neither G1 nor G2 fulfils the criteria for CKD.
Quest Diagnostics (test 375)
| Group | Range (mL/min/1.73 m²) |
|---|---|
| Adults | 60 or above |
Reported with every creatinine (test 375). Quest moved to the 2021 race-free equation on July 11, 2022. Result LOINC 98979-8.
An eGFR below 60 for three months or more defines chronic kidney disease. Without other evidence of kidney damage, categories G1 and G2 do not meet the criteria for CKD.
Units: eGFR is scaled to a standard body surface area of 1.73 m². To convert mL/min per 1.73 m² to mL/s per 1.73 m², multiply by 0.0167. [12]
Is there an "optimal" range?
One cut-off of 60 defines chronic kidney disease at every adult age, but GFR falls naturally with age, and some experts argue this labels many healthy older people as having kidney disease.
One threshold for all adults
Below 60 for three months or more
KDIGO GFR categories, as printed by Labcorp
An eGFR under 60 sustained for three months defines CKD. G1 and G2 count as CKD only with other evidence of kidney damage, such as a urine albumin-to-creatinine ratio above 30 mg/g.
Sources: [2]
Thresholds should allow for age and sex
Glassock and Winearls (2008, 2009)
A fixed threshold ignores the normal decline of GFR with age and sex, and creates many false positive CKD diagnoses, mostly in older people and women. They propose using the percentile distribution of eGFR by age and sex.
Healthy GFR is lower in older adults
Lowest death risk at 75 or above under age 55; 45-104 at 65 and older
Review of the ageing kidney (Denic, Glassock and Rule, 2016)
GFR fell 6.3 mL/min/1.73 m² per decade in screened kidney donors, and the GFR with the lowest risk of death is lower in older adults. The authors note that older people still have less reserve and higher risk of acute kidney injury.
Sources: [10]
What raises it
| Factor | How | How much |
|---|---|---|
| PregnancyPhysiology | Kidney blood flow and filtration rise markedly in normal pregnancy. | GFR up 40-65% [5] |
| Early diabetes (hyperfiltration)Condition | Many people early in diabetes have an abnormally high GFR, which may itself strain the kidneys. | Seen in 10-67% of people with type 1 and 6-73% with type 2 diabetes [6] |
| Low muscle massPhysiology | Less muscle means less creatinine, so creatinine-based eGFR reads high in frail, critically ill or cancer patients. | No published magnitude [2] [14] |
| Semaglutide or Dulaglutide in diabetic kidney diseasePeptide | In people with diabetes and kidney disease, semaglutide slowed the yearly fall in eGFR. See the peptide table below. | Yearly decline slower by 1.16 mL/min/1.73 m² vs placebo (a slower decline, not an absolute increase) [15] |
What lowers it
| Factor | How | How much |
|---|---|---|
| Chronic kidney diseaseCondition | Loss of working nephrons lowers filtration. An eGFR below 60 for three months or more defines CKD. | No published magnitude [2] |
| AgeingPhysiology | GFR declines with normal ageing, usually from 30-40 years. | 6.3 mL/min/1.73 m² per decade in screened kidney donors [10] [9] |
| A cooked-meat mealNutrition | A cooked-meat meal raises creatinine for hours, which lowers the calculated eGFR; cystatin C was not affected. | Median eGFR 84.0 before vs 59.5 mL/min/1.73 m² 1-2 hours after the meal [16] |
| Hard exerciseLifestyle | Resistance exercise raises creatinine, lowering eGFR for days. | About 10% lower in men and 8% in women after one session [17] |
| High muscle mass or creatine supplementsPhysiology | More creatinine from muscle or supplements makes eGFR read low even with normal kidneys. | No published magnitude [2] [18] |
| Drugs that block creatinine secretionMedication | Trimethoprim and dolutegravir raise creatinine by blocking its secretion, giving a falsely low eGFR while measured GFR is unchanged. | Dolutegravir: creatinine clearance down 10-14% with no change in measured GFR [19] [20] |
| FenofibrateMedication | Fenofibrate lowers eGFR in some people; in the ACCORD trial the change reversed after stopping. | eGFR 68.4 vs 77.8 mL/min/1.73 m² with placebo at trial end in those with the largest rise in creatinine; no different from placebo 51 days off the drug [21] |
| Somatostatin infusion and kidney-toxic peptidesPeptide | An IV somatostatin infusion lowers measured GFR while it runs, and colistin can reduce creatinine clearance. See the peptide table below. | IV somatostatin: measured GFR 112 to 93 mL/min at 120 minutes in normal subjects [22] [23] |
Peptides that affect eGFR
How each peptide in our library has been shown to affect eGFR or measured GFR, strongest evidence first. In kidney-disease trials, "raises" can mean a slower decline than the comparator rather than an absolute increase; each row says which. "No clear effect" means GFR was measured and did not change.
| Peptide | Effect on eGFR | Size of effect | Evidence |
|---|---|---|---|
| Atrial Natriuretic Peptide | Raises | RCT, 61 patients with ischemic acute renal failure after cardiac surgery: h-ANP 50 ng/kg/min improved creatinine clearance vs placebo (p = .040)Improved filtration in acute kidney failure after heart surgery. [24] | Human trials |
| Dulaglutide | Raises | AWARD-7 (type 2 diabetes with moderate-to-severe CKD, 52 weeks): eGFR (cystatin C) 34.0 with 1.5 mg weekly vs 31.3 mL/min/1.73 m² with insulin glargine (p = 0.005). A slower decline than with insulin glargine, not an absolute increaseLess eGFR decline over a year than with insulin glargine. The comparator was an active drug, not placebo. [25] | Human trials |
| Retatrutide | Raises | Post hoc analysis, overweight or obesity without diabetes, 48 weeks: creatinine-based eGFR 5.3 (95% CI 1.9-8.7) and 8.5 (4.9-12.1) mL/min/1.73 m² higher than placebo with 8 mg and 12 mg. A difference vs placebo, not an absolute increase; unchanged vs placebo in type 2 diabetesHigher doses raised eGFR relative to placebo in people with obesity (cystatin C eGFR rose too), but not in people with type 2 diabetes. Participants started with normal kidney function. [26] | Human trials |
| Semaglutide | Raises | FLOW trial (type 2 diabetes with CKD, 1.0 mg weekly, median 3.4 years): the yearly eGFR decline was 1.16 mL/min/1.73 m² slower than with placebo. A slower decline vs placebo, not an absolute increaseSlowed the yearly fall in eGFR in people with diabetes and kidney disease, so eGFR stayed higher than on placebo. [15] | Human trials |
| SS-31 | Raises | Same phase 2a (n=6 elamipretide vs 8 placebo): eGFR rose over 3 months after renal artery stenting (P=0.003) vs placebo (P=0.11)Small pilot in kidney-artery stenting: eGFR improved more with elamipretide than placebo. [27] | Human trials |
| Erythropoietin (EPO) | Lowers | Measured GFR (51Cr-EDTA) fell slightly on day 4 of 28 days of rHuEPO in healthy men (clearance studies in 8)A small, short-lived fall in filtration in healthy men; not seen later in the course. [28] | Human trials |
| Somatostatin | Lowers | IV somatostatin 100 ug/h, normal subjects: measured GFR (51Cr-EDTA) 112 to 93 mL/min at 120 min; 0.1 ug/kg/min in 46 healthy men: inulin GFR -14%An acute IV infusion lowers measured kidney filtration in healthy people by narrowing renal blood flow; effect seen during infusion. [22] [29] | Human trials |
| Adrenocorticotropic Hormone (ACTH) | No clear effect | Same pilot: eGFR 34 at baseline vs 21 mL/min at 18 months (16-unit group, P = 0.175); 39 vs 30 (32-unit group, P = 0.617)eGFR changes were not statistically significant, but the study was small and eGFR drifted down. [30] | Human trials |
| Adrenomedullin | No clear effect | Eight men with IgA nephropathy (plasma creatinine 0.19 mmol/L), vehicle-controlled infusion: creatinine clearance stableIn people with chronic kidney disease, an adrenomedullin infusion did not change measured creatinine clearance. [31] | Human trials |
| Carnosine | No clear effect | Type 2 diabetic nephropathy RCT, 12 weeks of oral carnosine: glomerular filtration rate unchangedeGFR did not change, although urinary TGF-beta (a kidney-injury marker) fell. [32] | Human trials |
| Cotadutide | No clear effect | eGFR change +1.17 vs -1.10 mL/min/1.73 m² with placebo (p = .268) over 32 days (50 to 300 µg titrated) in type 2 diabetes with chronic kidney disease (21 on cotadutide)Short, small phase 2a study in people with CKD; no measurable eGFR change. [33] | Human trials |
| IGF-1 (Insulin-Like Growth Factor 1) | No clear effect | Placebo-controlled trial, acute renal failure (n=72), rhIGF-I 100 ug/kg SC every 12 h for about 10.7 days: no difference in GFR change vs placeboIn acute kidney failure, IGF-1 did not improve or worsen measured kidney filtration. [34] | Human trials |
| Lanreotide | No clear effect | DIPAK 1: 305 adults with ADPKD (eGFR 30-60), lanreotide 120 mg SC every 4 weeks for 2.5 years: eGFR decline -3.53 vs -3.46 mL/min/1.73 m2 per year with standard care (P = .81)In later-stage polycystic kidney disease, lanreotide did not change the rate of eGFR decline. [35] | Human trials |
| Liraglutide | No clear effect | Same meta-analysis (type 2 diabetic nephropathy): eGFR WMD -0.81, p = 0.21 vs no liraglutidePooled trials found no significant eGFR difference with liraglutide in diabetic kidney disease. [36] | Human trials |
| Lixisenatide | No clear effect | ELIXA (type 2 diabetes after acute coronary syndrome, 108 weeks): no significant eGFR difference vs placebo in any albuminuria subgroupeGFR declined similarly with lixisenatide and placebo. [37] | Human trials |
| Nesiritide | No clear effect | ASCEND-HF, 7141 patients with acute heart failure, 24-168 h infusion: eGFR fall >25% in 31.4% vs 29.5% placebo (OR 1.09, P = 0.11)In the largest trial, nesiritide did not significantly increase worsening of eGFR. [38] | Human trials |
| Tirzepatide | No clear effect | Meta-analysis of 8 RCTs (9533 people with type 2 diabetes): eGFR MD 0.39 mL/min/1.73 m2 (95% CI -0.64 to 1.42; P=.46); albuminuria fell 26.9%No measurable change in eGFR across the pooled trials, while urine albumin fell. [39] | Human trials |
| Colistin | Lowers | FDA label lists decreased creatinine clearance among laboratory deviations; nephrotoxicity is dose-dependent and reversible after stoppingKidney filtration can fall during colistin treatment. [23] | FDA label |
| Teriparatide | No clear effect | Forteo clinical studies: creatinine clearance assessed, no clinically important adverse renal effectsLabel reports no clinically important change in kidney filtration (creatinine clearance) in trials. [40] | FDA label |
| ARA-290 | Raises | Pigs with 45-min renal ischemia: GFR of the injured kidney (creatinine clearance) higher with ARA-290 over 7 days (p < 0.05)Improved measured filtration in a pig kidney-injury model. No human data. [41] | Animal studies |
| Galanin | Raises | Measured GFR +14% at 100 and +33% at 200 ng/kg/min intrarenal infusion in anesthetized dogs; no change at 50 ng/kg/minAcute dog study; the rise went with higher blood glucose. [42] | Animal studies |
| Alpha-Melanocyte-Stimulating Hormone (α-MSH) | Lowers | Pig kidney transplants from brain-dead donors: alpha-MSH reduced urine flow and impaired recovery of measured GFR compared with controlsIn pig kidney transplants alpha-MSH slowed GFR recovery, unlike the rodent ischemia results. No human data. [43] | Animal studies |
What high or low results can mean
A high result
An eGFR of 90 or above is normal or high filtering. Very high values can reflect low muscle mass, pregnancy or early diabetic hyperfiltration rather than especially healthy kidneys.
- Normal kidney function in a younger adult
- Pregnancy
- Early diabetes (hyperfiltration)
- Low muscle mass, which makes creatinine-based eGFR read high
A low result
An eGFR below 60 on repeat tests over three months defines chronic kidney disease. A single low value can be temporary, from dehydration, a meat meal, exercise or drugs that block creatinine secretion.
- Chronic kidney disease
- Acute kidney injury or dehydration
- Ageing
- A cooked-meat meal or hard exercise before the test
- High muscle mass or creatine supplements
- Trimethoprim, dolutegravir or fenofibrate
How the test works
| Sample | Calculated from serum creatinine. Labcorp prefers serum (lithium-heparin plasma accepted; not oxalate, EDTA or citrate plasma) and rejects hemolyzed samples. Quest reports eGFR with every creatinine (test 375) from 1 mL of serum or heparin plasma. |
|---|---|
| Fasting | No fasting is required, but a cooked-meat meal on the day of the test can lower eGFR for hours; a fasting sample or one taken without cooked meat that day is more reliable. |
| Timing | Avoid hard exercise for a few days beforehand. Chronic kidney disease is diagnosed only when eGFR stays below 60 for three months or more, so a low value is repeated. |
| Lab differences | Both labs use the CKD-EPI 2021 creatinine equation without race. Creatinine-based estimates are less accurate at the extremes of muscle mass, with unusual diets and when creatinine secretion is reduced; KDIGO recommends cystatin C for confirmation in those cases, and a creatinine-cystatin C equation (LOINC 98980-6) is more accurate. |
| Retesting | From normal biological and analytical variation, two eGFR results need to differ by roughly 12.5-16.5% before the change is likely to be real. |
| Labcorp order code | 100768: Glomerular Filtration Rate, Estimated (eGFR) |
| Quest Diagnostics order code | 375: Creatinine (includes eGFR) |
| LOINC codes |
|
History
Estimating kidney function from creatinine began with the Cockcroft-Gault formula in 1976. The MDRD (1999) and CKD-EPI (2009) equations that followed multiplied the result for patients identified as Black. Race is a social, not a biologic, construct, and the multiplier gave Black patients higher estimates that delayed specialist referral and transplant listing. A 2021 race-free equation replaced it at US labs in 2022.
- 1976Cockcroft and Gault publish a formula predicting creatinine clearance from serum creatinine, age and body weight, with a value 15% lower for women. [48]
- 1999The MDRD Study equation, built from 1,628 patients with kidney disease, estimates GFR from creatinine, age, sex, Black race and other blood values. As later re-expressed, it multiplied the estimate by 1.212 for Black patients. [49] [12]
- 2009The CKD-EPI equation (8,254 participants in 10 studies) proves more accurate than MDRD, especially at higher GFR. It multiplies the estimate by 1.159 for Black patients. [12]
- 2021Inker and colleagues publish CKD-EPI equations without race, noting that race in eGFR equations is a social and not a biologic construct. In September an NKF-ASN task force releases the race-free creatinine equation and recommends its immediate implementation in all US labs. [4] [45] [3]
- 2022Labcorp switches to the race-free CKD-EPI 2021 equation on Feb. 28; Quest follows on July 11. Labcorp notes the new values are slightly lower for people who identify as Black and slightly higher for others. [50] [3]
- 2023From Jan. 5 the OPTN requires kidney transplant programs to review Black candidates for waiting-time credit lost to race-based eGFR. In 2023, 32% of Black candidate listings received a modification, a median of 610 extra priority days; by mid-2025, 21,119 candidates had received one. [51] [52]
FAQ
What is a normal eGFR?
Labcorp reports above 59 mL/min/1.73 m² as normal and Quest 60 or above. A healthy young adult is typically about 120-130, and the value falls with age.
What eGFR means chronic kidney disease?
An eGFR below 60 for three months or more. Stages run from G1 (90 or above) to G5 (below 15); G1 and G2 count as kidney disease only with other evidence of kidney damage, such as albumin in the urine.
Sources: [2]
Does eGFR still use race?
No, not at Labcorp or Quest. Both switched in 2022 (Labcorp on Feb. 28, Quest on July 11) to the CKD-EPI 2021 creatinine equation, which uses creatinine, age and sex only.
Why was race ever in the equation?
The MDRD and CKD-EPI 2009 equations were fitted with a multiplier for patients identified as Black (1.212 and 1.159). Race is a social, not a biologic, construct, and the higher estimates delayed specialist referral and transplant listing for Black patients. Since January 2023 the national transplant network has required programs to credit Black candidates for waiting time lost to race-based eGFR.
Did the new equation change my number?
Slightly. Labcorp notes that values from the 2021 equation are slightly lower for people who identify as Black and slightly higher for others, with similar overall performance to the 2009 equation.
Sources: [50]
Can diet or exercise affect eGFR?
Yes, through creatinine. A cooked-meat meal dropped median eGFR from 84.0 to 59.5 within 1-2 hours, and one resistance-exercise session lowered it by about 8-10%. Test after avoiding both.
Is eGFR accurate if I am very muscular or take creatine?
Less so. Creatinine-based eGFR is least accurate at the extremes of muscle mass and with unusual diets, and creatine supplements can raise creatinine with healthy kidneys. Cystatin C, alone or with creatinine, gives a better estimate.
What is cystatin C and when is it used?
A second filtration marker. It was not affected by a cooked-meat meal and can improve estimates when muscle mass is changing. The 2024 KDIGO guideline recommends equations combining creatinine and cystatin C for diagnosing and staging kidney disease, and they are more accurate than creatinine alone.
Does eGFR fall with age?
Yes. GFR usually starts declining after 30-40 years; in carefully screened kidney donors it fell 6.3 mL/min/1.73 m² per decade. Some experts argue the fixed threshold of 60 over-diagnoses kidney disease in older adults.
Can peptides affect eGFR?
In kidney-disease trials Semaglutide slowed the yearly decline by 1.16 vs placebo, and Dulaglutide kept eGFR higher than insulin glargine. Tirzepatide, Liraglutide and Lixisenatide showed no significant eGFR change, and an IV Somatostatin infusion lowers measured GFR while it runs.
Can medications lower eGFR without harming the kidneys?
Yes. Trimethoprim and dolutegravir block creatinine secretion, raising creatinine and lowering eGFR while measured GFR stays the same. The change reverses when the drug is stopped.
How much does eGFR vary between tests?
Two results need to differ by roughly 12.5-16.5% before the change is likely to be real, because of normal day-to-day and analytical variation in creatinine.
Sources: [47]
References
- Creatinine Clearance. In: StatPearls [Internet]. StatPearls Publishing; 2024. PMID 31334948
- Labcorp. Test 100768: Glomerular Filtration Rate, Estimated (eGFR). Equation, limitations, GFR categories, reference interval and LOINC map. labcorp.com/tests/100768/glomerular-filtration-rate-estimated-egfr
- Quest Diagnostics. Test changes effective 7/11/2022: transition of eGFR reporting to the 2021 race-free (CKD-EPI 2021cr) equation (IntelliTest Manager notice 232586). intellitestmanager.questdiagnostics.com/home/output/232586
- Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-1749. PMID 34554658
- Jeyabalan A, Conrad KP. Renal function during normal pregnancy and preeclampsia. Front Biosci. 2007;12:2425-37. PMID 17127252
- Tonneijck L, Muskiet MH, Smits MM, et al. Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. J Am Soc Nephrol. 2017;28(4):1023-1039. PMID 28143897
- Kim GH. Renal effects of prostaglandins and cyclooxygenase-2 inhibitors. Electrolyte Blood Press. 2008;6(1):35-41. PMID 24459520
- Chiou WL, Hsu FH. Pharmacokinetics of creatinine in man and its implications in the monitoring of renal function and in dosage regimen modifications in patients with renal insufficiency. J Clin Pharmacol. 1975;15(5-6):427-34. PMID 1133219
- Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc. 2009;120:419-28. PMID 19768194
- Denic A, Glassock RJ, Rule AD. Structural and Functional Changes With the Aging Kidney. Adv Chronic Kidney Dis. 2016;23(1):19-28. PMID 26709059
- Quest Diagnostics. Test code 375: Creatinine (includes eGFR). Test directory entry (East region): methodology, specimen, reference ranges and LOINC. testdirectory.questdiagnostics.com/test/test-detail/375/creatinine?cc=PHP
- Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12. PMID 19414839
- Glassock RJ, Winearls C. Screening for CKD with eGFR: doubts and dangers. Clin J Am Soc Nephrol. 2008;3(5):1563-8. PMID 18667744
- Labcorp. Test 001370: Creatinine. Methodology, use, limitations, interfering substances, reference intervals and LOINC map. labcorp.com/tests/001370/creatinine
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. PMID 38785209
- Preiss DJ, Godber IM, Lamb EJ, et al. The influence of a cooked-meat meal on estimated glomerular filtration rate. Ann Clin Biochem. 2007;44(Pt 1):35-42. PMID 17270090
- Amorim MZ, Machado M, Hackney AC, et al. Sex differences in serum CK activity but not in glomerular filtration rate after resistance exercise: is there a sex dependent renal adaptative response?. J Physiol Sci. 2014;64(1):31-6. PMID 24037727
- Williamson L, New D. How the use of creatine supplements can elevate serum creatinine in the absence of underlying kidney pathology. BMJ Case Rep. 2014;2014. PMID 25239988
- Delanaye P, Mariat C, Cavalier E, et al. Trimethoprim, creatinine and creatinine-based equations. Nephron Clin Pract. 2011;119(3):c187-93; discussion c193-4. PMID 21832843
- Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;75(4):990-6. PMID 22905856
- Mychaleckyj JC, Craven T, Nayak U, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care. 2012;35(5):1008-14. PMID 22432114
- Vora J, Owens DR, Luzio S, et al. Renal response to intravenous somatostatin in insulin-dependent diabetic patients and normal subjects. J Clin Endocrinol Metab. 1987;64(5):975-9. PMID 2881944
- COLY-MYCIN M Parenteral (colistimethate for injection), prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d6e13e2-dc33-4b7b-84d0-66146a57c552
- Swärd K, Valsson F, Odencrants P, et al. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med. 2004;32(6):1310-5. PMID 15187512
- Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605-617. PMID 29910024
- Heerspink HJL, Lu Z, Du Y, et al. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Kidney Int Rep. 2025;10(6):1980-1992. PMID 40630318
- Saad A, Herrmann SMS, Eirin A, et al. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis. Circ Cardiovasc Interv. 2017;10(9). PMID 28916603
- Olsen NV, Aachmann-Andersen NJ, Oturai P, et al. Erythropoietin down-regulates proximal renal tubular reabsorption and causes a fall in glomerular filtration rate in humans. J Physiol. 2011;589(Pt 6):1273-81. PMID 20724370
- Schmidt A, Pleiner J, Schaller G, et al. Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release. Kidney Int. 2002;61(5):1788-93. PMID 11967028
- Tumlin JA, Galphin CM, Rovin BH. Advanced diabetic nephropathy with nephrotic range proteinuria: a pilot study of the long-term efficacy of subcutaneous ACTH gel on proteinuria, progression of CKD, and urinary levels of VEGF and MCP-1. J Diabetes Res. 2013;2013:489869. PMID 24159603
- McGregor DO, Troughton RW, Frampton C, et al. Hypotensive and natriuretic actions of adrenomedullin in subjects with chronic renal impairment. Hypertension. 2001;37(5):1279-84. PMID 11358941
- Siriwattanasit N, Satirapoj B, Supasyndh O. Effect of Oral carnosine supplementation on urinary TGF-β in diabetic nephropathy: a randomized controlled trial. BMC Nephrol. 2021;22(1):236. PMID 34174842
- Parker VER, Hoang T, Schlichthaar H, et al. Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2022;24(7):1360-1369. PMID 35403793
- Hirschberg R, Kopple J, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int. 1999;55(6):2423-32. PMID 10354291
- Meijer E, Visser FW, van Aerts RMM, et al. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial. JAMA. 2018;320(19):2010-2019. PMID 30422235
- Mali N, Su F, Ge J, et al. Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. BMC Endocr Disord. 2022;22(1):93. PMID 35392872
- Muskiet MHA, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):859-869. PMID 30292589
- O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32-43. PMID 21732835
- Karakasis P, Patoulias D, Fragakis N, et al. Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis. Diabetes Obes Metab. 2024;26(3):1090-1104. PMID 38116693
- FORTEO (teriparatide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0
- van Rijt WG, Nieuwenhuijs-Moeke GJ, van Goor H, et al. ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury. J Transl Med. 2013;11:9. PMID 23302512
- Premen AJ. Renal hemodynamic response to galanin: importance of elevated plasma glucose. Regul Pept. 1989;26(3):277-85. PMID 2482984
- van Rijt WG, Secher N, Keller AK, et al. α-Melanocyte stimulating hormone treatment in pigs does not improve early graft function in kidney transplants from brain dead donors. PLoS One. 2014;9(4):e94609. PMID 24728087
- Awdishu L, Karger AB, Shlipak MG, et al. Use of Cystatin C in Tandem with Creatinine to Improve GFR Estimation and Clinical Decision Making. J Am Soc Nephrol. 2026;37(9):2042-2054. PMID 42424121
- Delgado C, Baweja M, Crews DC, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am J Kidney Dis. 2022;79(2):268-288.e1. PMID 34563581
- LOINC 98979-8: Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M. Regenstrief Institute. Record checked through the NLM Clinical Table Search Service. loinc.org/98979-8
- Thöni S, Keller F, Denicolò S, et al. Biological variation and reference change value of the estimated glomerular filtration rate in humans: A systematic review and meta-analysis. Front Med (Lausanne). 2022;9:1009358. PMID 36275823
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. PMID 1244564
- Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-70. PMID 10075613
- Labcorp. Labcorp Implements Race-Free Equation for Kidney Disease Test. Press release, March 2, 2022 (change implemented Feb. 28, 2022). labcorp.com/labcorp-implements-race-free-equation-kidney-disease-test
- Schold JD, Arrigain S, Husain SA, et al. Variation of eGFR Wait Time Modifications for Black Kidney Transplant Candidates in the United States. J Am Soc Nephrol. 2025;36(10):2019-2029. PMID 40327843
- Khazanchi R, Fleishman A, Eneanya ND, et al. Wait Time Modifications for Black Transplant Candidates Affected by Race-Based Kidney Function Estimation. JAMA Intern Med. 2026;186(5):517-530. PMID 41801177
- Berglund F, Killander J, Pompeius R. Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. J Urol. 1975;114(6):802-8. PMID 1195454
Educational information, not medical advice. Lab ranges, equations and test codes were checked on October 29, 2026. Always use the range printed on your own report, and talk to a clinician about your results.